Marijuana Rescheduling: Where Schedule III Stands and What It Changes for Edibles Buyers

Schedule III changes a dispensary's tax bill and a researcher's paperwork. It leaves alone the question most readers are actually asking, whether the gummy is legal to buy, because your state answers that, the same way it did before April 28, 2026. The large impacts DEA flagged in its own rule were to "Federal taxes and research and development investment for the pharmaceutical industry, among other things." The gummy is presumably an other thing.

Today marijuana sits in two schedules at once. FDA-approved drugs and marijuana under a state medical license have been in Schedule III since April 28. Everything else, adult-use included, stays in Schedule I while DEA's broader proceeding waits on a judge with no deadline. The news articles carry this story piecemeal. This page owns the status, and each weekly sweep updates it.

One federal line has moved for patients. On October 30, 2026 the Justice Department announced the first federal registrations for more than 900 dispensaries in seven states, none with an operating adult-use market. A registered patient in Texas can now buy from a store with a federal registration. In Minneapolis, DEA has told one dispensary its dual-purpose license does not count, and Minnesota says medical cannabis stays available under state law anyway.

Is marijuana Schedule III now?

Partly. Since April 28, 2026, FDA-approved marijuana drugs and marijuana under a state medical license sit in Schedule III. All other marijuana, adult-use included, stays in Schedule I. As of November 7, 2026, the Federal Register shows no final rule moving the rest, and we found no report of the judge's recommended decision.

This table shows each track that decides the answer, who controls it, its last action and its next date.

The two tracks touch. If the D.C. Circuit holds that the Attorney General cannot reschedule by order, the medical category returns to Schedule I until the formal rulemaking finishes, and that rulemaking is the one with no clock.

What does Schedule III change for someone buying a dispensary edible?

Very little at the counter. Your state still decides whether you can buy, what dose and what package size. Schedule III takes a federal tax penalty off qualifying operators, opens licensed products to registered research, and since October 30 gives some medical stores a federal registration. A sale to an adult-use customer stays outside federal permission either way.

This table compares the medical channel today, the adult-use channel today, and both after a final rule covering all marijuana.

For anyone using edibles as medicine, the research clause is the sleeper. The rule says a DEA-registered researcher who buys from a federally registered state licensee incurs no liability for that reason alone, which means the products people actually buy can enter federally registered studies. The executive order behind all this is titled Increasing Medical Marijuana and Cannabidiol Research, and the medical-use evidence has been waiting on exactly that.

Prices are where the promises outrun the paper. Treasury says the relief generally first applies to the full taxable year that includes the order's effective date, and the rule itself disclaims any finding on tax liability. That is a margin story for operators. No document on this page sets a shelf price.

Which dispensaries has DEA registered, and why not yours?

More than 900 dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia, announced October 30, 2026. None sits in a state with an operating adult-use market. DEA has moved against a Minneapolis store on the ground that a license covering both medical and adult-use sales falls outside its definition.

DEA's own list shows the queue. The file dated November 7, 2026 holds 6,046 pending entries: 3,261 dispensaries, 2,075 manufacturers and 710 distributors, across 44 states and territories. Oklahoma alone accounts for 2,442 of them, about 40 percent, which is a lot of federal paperwork for one state's medical program. California has 491 dispensary entries. Alabama, Virginia and West Virginia have no dispensary entries left and Texas has one, which fits DEA's note that the list changes as registrations are granted.

Being on the list matters. Under DEA's timely applicant guidance, a store that applied between April 28 and June 26 can keep dispensing under its state license while the application is pending. It can only take new stock from other registrants or timely applicants, and DEA expects those supply chains in place by November 29, 2026. Existing inventory can still be sold. Attorney Rod Kight warns the restriction can disrupt established businesses, and whether a medical-only license inside an adult-use state qualifies remains unclear.

The Minnesota order is the one to watch. Per a digest of the Star Tribune's report, the store can ask for a hearing within 30 days or offer a corrective plan, and the state's Office of Cannabis Management says the letter does not affect state law and medical cannabis remains available to patients. Same molecule, two federal answers, and both sales legal where they happen.

When will all marijuana move to Schedule III?

No date exists. Judge Julius owes a recommended decision with no deadline, the parties then get 20 days for exceptions, and the DEA Administrator makes the final call, bound by nothing. That decision can then be challenged in federal court. A final rule in the Federal Register is the only thing that changes the schedule.

1. Recommended decision from Judge Julius. Non-binding, no deadline.
2. Exceptions from the parties, 20 days.
3. The record goes to Administrator Cole, who issues a final rule or does not. No deadline.
4. Petitions for review in a federal appeals court.

Precedent offers no comfort on speed. In the last full fight of this kind, Judge Francis Young recommended rescheduling in 1988, the Administrator rejected the recommendation, and the D.C. Circuit approved the rejection in 1994. The current hearing notice promises the opposite, citing the president's order to finish "in the most expeditious manner," and then a GAO report cost the case about five weeks. That report's own title says DEA decisions "Have Aligned with Recent HHS Recommendations": on all 84 substances with a final rule from 2020 through 2025, DEA matched HHS, and HHS recommended Schedule III for marijuana in August 2023. The gap GAO found is in written procedures. Opponents wanted a new hearing over it, and the judge gave them ten pages.

Does rescheduling change the hemp ban?

No. Section 781 is a separate statute on its own clock: November 12, 2026 for cannabinoids the plant cannot produce, December 11 for the rest. The April order reaches marijuana "that falls outside the definition of hemp" only inside an FDA-approved drug or under a state medical license, so a hemp product over the cap lands in Schedule I.

The hemp ban pillar covers what closes and when.

What has happened on rescheduling so far, newest first?

Seven months of filings and no final word on adult-use. The April 28 order moved the medical category, the hearing ran June 29 to July 15, a GAO report paused the case from September 29 through the November 5 briefing close, and the first dispensary registrations landed October 30. Each sweep adds to the top of this log.

• November 7, 2026. Check: the Federal Register API shows no marijuana final rule after April 28, and DEA's applicant file holds 6,046 entries.
• November 5, 2026. Reply briefs on the GAO report. DEA asked again for no weight; NDASA, DUID Victim Voices and Dr. Kenneth Finn asked Judge Julius to recommend that Administrator Terry Cole reject rescheduling on the existing record. Briefing closed, so the stay expired on the terms of the October 22 order. As of November 9 we found no report of a recommended decision, and none is due by any deadline.
• October 30, 2026. The Justice Department announced the first dispensary registrations; manufacturer and distributor applications remain under review. DEA published its timely applicant guidance. An order against a Minnesota dispensary surfaced the same day.
• October 29, 2026. Briefs on the GAO report. DEA asked for no weight. NDASA, DUID Victim Voices and Dr. Kenneth Finn asked for decisive weight and a new HHS evaluation. Smart Approaches to Marijuana, with Idaho, Indiana and Nebraska, asked that marijuana stay in Schedule I. The Tennessee Bureau of Investigation backed the opponents.
• October 22, 2026. Judge Julius denied reopening, admitted the GAO report, and set optional ten-page briefs. The record already held more than 2,500 pages of testimony. Our coverage.
• October 9, 2026. The Justice Department and the challengers proposed a D.C. Circuit schedule: opening brief November 24, government's response January 13, 2027, reply February 5, final briefs February 19. The court had not adopted it as of October 27.
• September 29, 2026. Judge Julius stayed the hearing to weigh a motion on the GAO report. The same day Treasury's 2026-2027 plan listed "Guidance under §280E."
• September 23, 2026. GAO-26-108623 published, with three recommendations on written policies, and the agencies concurred with all three.
• September 9, 2026. The D.C. Circuit denied a stay, saying petitioners "have not satisfied the stringent requirements." It also turned away two medical operators as intervenors and let them in as amici. Our coverage.
• August 17, 2026. Closing briefs: DEA for Schedule III, seven opposition parties against. Our coverage.
• June 29 to July 15, 2026. The hearing in Arlington. Every designated party opposed the rule, NORML was refused a seat, and DEA defended its own proposal. Our wrap.
• June 9, 2026. NDASA and MMJ International moved for a stay. The drug-testing group told the court marijuana-positive results are the largest revenue source for its medical review officers.
• May 4 to 28, 2026. Three petitions for review: Smart Approaches to Marijuana, then Nebraska and Indiana, then a coalition including MMJ International.
• April 28, 2026. The final order took effect, a new hearing was noticed, and the 2024 hearing notice was withdrawn.
• December 18, 2025. Executive Order 14370 told the Attorney General to complete the rulemaking.
• May 21, 2024. The Justice Department proposed moving all marijuana to Schedule III (89 FR 44597), following HHS's August 2023 recommendation.

If you hold a DEA order, a filing or a registration letter we cannot reach, send it to hello@ediblerank.com.